论文部分内容阅读
干细胞移植治疗缺血性心肌病作为一种新型的治疗方法,无论基础研究还是临床研究都显示出其特有的疗效和潜在的前景。但是一种治疗方法的出现,需要长期的基础研究和临床观察。当前干细胞移植治疗缺血性心肌病在全世界多中心展开,大量的循证医学证据表明其优势效应的同时,也暴露出其存在的问题。因此对于一种新型治疗方式,应该辩证地去看待其优势和弊端。
Stem cell transplantation for the treatment of ischemic cardiomyopathy as a new treatment, both in basic research and clinical studies have shown its unique efficacy and potential prospects. However, the emergence of a treatment method requires long-term basic research and clinical observation. The current stem cell transplantation for the treatment of ischemic cardiomyopathy in many centers around the world, a large number of evidence-based medical evidence that its dominant effects, but also exposed its existing problems. So for a new type of treatment, it should be a dialectical view of its advantages and disadvantages.